MetaVia has posted eye-catching Phase 1 data for DA-1726, its dual GLP-1/glucagon agonist, showing fast, deep metabolic effects in just eight weeks, without dose titration.
This is early-stage data. But the signals are hard to ignore.
The Headline Numbers (Day 54)
At a non-titrated 48 mg dose, DA-1726 achieved:
- 9.1% body weight reduction (21.2 lbs)
- 9.8 cm waist circumference reduction (p = 0.006)
- 12.3 mg/dL reduction in fasting glucose
- 23.7% reduction in liver stiffness (VCTE)
- Zero treatment-related discontinuations
All within 54 days.
Why This Data Stands Out?
Most obesity drugs ease patients into higher doses. DA-1726 did not. Patients received a fixed 48 mg dose from Day 1, yet still showed:
- Mild-to-moderate GI events
- No treatment-related dropouts
- Progressive improvements over time
That combination matters. Fast efficacy without titration could become a real-world advantage.
Weight Loss: Fast and Still Improving
- Day 26:
- 6.1% weight loss (p = 0.003)
- 5.8 cm waist reduction (p = 0.006)
- Day 54:
- 9.1% weight loss
- 9.8 cm waist reduction (p = 0.022)
The continued drop suggests the curve had not yet flattened.
Waist Reduction Signals Visceral Fat Loss
MetaVia is leaning into this point. The company believes the glucagon receptor activity may be driving:
- Greater visceral fat reduction
- Larger waist circumference changes
- Potential differentiation versus GLP-1–only drugs
If confirmed, this could matter for cardiometabolic risk, not just scale weight.
Glucose and Liver Effects Add a Second Layer
DA-1726 didn’t trade weight loss for glycemic control.
Instead:
- Fasting glucose fell 12.3 mg/dL
- A prediabetic subject saw HbA1c drop from 6.0% to 5.5%
- Liver stiffness declined 23.7% by VCTE
VCTE is:
- FDA-recognized
- Widely used in MASH development
- A meaningful early hepatic signal
Seeing this change in eight weeks is notable.
Safety and Tolerability
The basics held up:
- No treatment-related discontinuations
- GI events were mild to moderate
- No unexpected safety signals reported
That matters if MetaVia wants faster titration—or none at all.
What DA-1726 Is Competing Against?
DA-1726 is positioned as a dual GLP-1/glucagon agonist, inspired by oxyntomodulin biology.
Preclinical comparisons suggest:
- Greater energy expenditure than GLP-1 alone
- Comparable or better weight loss than semaglutide
- Lean mass preservation advantages versus some peers
Phase 1 data now suggests this may translate clinically.
What Comes Next?
MetaVia plans 16-week titration studies:
- Single-step escalation to 48 mg
- Two-step escalation to 64 mg
Data is expected in Q4 2026.
The company believes faster titration—and stronger early effects—could become a competitive edge in both clinical adoption and reimbursement.
Bottom Line
DA-1726 is still early. But in eight weeks, it delivered:
- Meaningful weight loss
- Large waist reduction
- Glucose improvement
- Early liver benefit
- Clean tolerability
If these signals hold in longer studies, MetaVia may be building more than just another obesity drug, it may be shaping a metabolic platform.
